AcelRx Pharmaceuticals (ACRX) Reports In-Line Q3 Loss of 38c/Share

AcelRx Pharmaceuticals (NASDAQ: ACRX) reported Q3 EPS of ($0.38), in-line with the analyst estimate of ($0.38). Revenue for the quarter came in at $166 thousand versus the consensus estimate of $320 thousand.

For earnings history and earnings-related data on AcelRx Pharmaceuticals (ACRX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c